Growing demand for controlled release formulations reflects the need for enhanced patient comfort across diverse APIs. These formulations reduce dosing frequency—benefiting pediatric and geriatric patients especially—while increasing bioavailability and minimizing side effects. Clariant offers specialized PEGs and PEG-derivatives that precisely modify API dissolution rates, supporting effective product lifecycle extension through reformulation